The Young Ophthalmologist Perspective

<p>In this interview with <strong>Joseph Nezgoda, MD, MBA,</strong> we discuss young ophthalmologists – or YOs – and the most important challenges this group faces. Nezgoda also provides his insight and advice for YOs embarking on their career.</p> <ul> <li>Intro <strong><em>:13</em></strong></li> <li>In this episode <strong><em>:15</em></strong></li> <li>About Dr. Nezgoda <strong><em>:23</em></strong></li> <li>The interview <strong><em>:54</em></strong></li> <li>Who is Dr. Nezgoda? <strong><em>1:29</em></strong></li> <li>“Ah-ha” moments <strong><em>4:13</em></strong></li> <li>What is a young ophthalmologist, or YO? <strong><em>8:07</em></strong></li> <li>What is the most important topic or challenge currently facing YOs? <strong><em>9:57</em></strong></li> <li>What’s the ideal path – academic, private practice, or a hybrid? <strong><em>11:41</em></strong></li> <li>How did you get involved in advocacy? <strong><em>16:24</em></strong></li> <li>What do you think will be the biggest challenge for YOs in the future? <strong><em>22:42</em></strong></li> <li>Any last advice for YOs starting their career? <strong><em>26:53</em></strong></li> <li>Thanks for listening! <strong><em>29:35</em></strong></li> </ul> <p><strong>Joseph Nezgoda, MD, MBA,</strong> is an ophthalmologist and retina specialist in private practice at Retina Macula Institute in West Palm Beach, Fla. He is also vice president of education at Florida Society of Ophthalmology; editor of ONE Network Retina, American Academy of Ophthalmology; and delegate to the AMA, American Society of Retina Specialists.</p> <p><strong>Disclosures:</strong> Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novart